Litcius/Paper detail

Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial

Marc P. Bonaca, Andrei‐Mircea Catarig, Kim Christian Houlind, Bernhard Ludvik, Joakim Nordanstig, Chethana Ramesh, Neda Rasouli, Harald Sourij, Alex N. Videmark, Subodh Verma

2025The Lancet112 citationsDOI

Topics & Concepts

SemaglutideMedicineType 2 diabetesPlaceboSTRIDEArterial diseaseDiabetes mellitusPhysical therapyPeripheralInternal medicineDouble blindRandomized controlled trialPhysical medicine and rehabilitationCardiologyVascular diseaseEndocrinologyAlternative medicinePathologyLiraglutidePeripheral Artery Disease ManagementDiagnosis and Treatment of Venous DiseasesDiabetes Treatment and Management
Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial | Litcius